Ibrutinib-associated pityriasis rosea–like rash

CLL: chronic lymphocytic leukemia PR: pityriasis rosea EGFR: epidermal growth factor receptor PDGFR: platelet-derived growth factor receptor I brutinib, a Bruton tyrosine kinase inhibitor, is a new oral agent approved for the treatment of chronic lymphocytic leukemia (CLL). Ibrutinib is well-tolerated, with the majority of its adverse events within grade 1 or 2 severity. The most common nonhematologic side effects are diarrhea, arthralgia, rash, and brittle nails. Three subtypes of ibrutinib-related dermatitis have been reported in the literature: 1) asymptomatic nonpalpable petechial rash, 2) leukocytoclastic vasculitiselike pruritic violaceous palpable purpura, and 3) painless nonpruritic edematous papules with centripetal spread. We report a previously undescribed case of a pityriasis rosea (PR)elike dermatitis associated with the use of ibrutinib.